|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CENPE |
Gene summary for CENPE |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CENPE | Gene ID | 1062 |
| Gene name | centromere protein E | |
| Gene Alias | CENP-E | |
| Cytomap | 4q24 | |
| Gene Type | protein-coding | GO ID | GO:0000070 | UniProtAcc | Q02224 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1062 | CENPE | LZE2T | Human | Esophagus | ESCC | 1.36e-02 | 6.84e-01 | 0.082 |
| 1062 | CENPE | P2T-E | Human | Esophagus | ESCC | 1.00e-06 | 3.91e-01 | 0.1177 |
| 1062 | CENPE | P4T-E | Human | Esophagus | ESCC | 1.43e-07 | 4.59e-01 | 0.1323 |
| 1062 | CENPE | P5T-E | Human | Esophagus | ESCC | 1.86e-03 | 2.59e-01 | 0.1327 |
| 1062 | CENPE | P9T-E | Human | Esophagus | ESCC | 7.34e-03 | 2.04e-01 | 0.1131 |
| 1062 | CENPE | P10T-E | Human | Esophagus | ESCC | 1.78e-03 | 2.47e-01 | 0.116 |
| 1062 | CENPE | P15T-E | Human | Esophagus | ESCC | 8.20e-03 | 2.14e-01 | 0.1149 |
| 1062 | CENPE | P17T-E | Human | Esophagus | ESCC | 4.43e-02 | 2.89e-01 | 0.1278 |
| 1062 | CENPE | P21T-E | Human | Esophagus | ESCC | 4.25e-04 | 2.82e-01 | 0.1617 |
| 1062 | CENPE | P24T-E | Human | Esophagus | ESCC | 9.68e-05 | 2.80e-01 | 0.1287 |
| 1062 | CENPE | P26T-E | Human | Esophagus | ESCC | 3.67e-06 | 3.05e-01 | 0.1276 |
| 1062 | CENPE | P28T-E | Human | Esophagus | ESCC | 3.85e-07 | 2.53e-01 | 0.1149 |
| 1062 | CENPE | P30T-E | Human | Esophagus | ESCC | 2.28e-03 | 4.27e-01 | 0.137 |
| 1062 | CENPE | P32T-E | Human | Esophagus | ESCC | 1.19e-13 | 5.23e-01 | 0.1666 |
| 1062 | CENPE | P37T-E | Human | Esophagus | ESCC | 2.49e-07 | 3.58e-01 | 0.1371 |
| 1062 | CENPE | P40T-E | Human | Esophagus | ESCC | 3.14e-04 | 2.50e-01 | 0.109 |
| 1062 | CENPE | P47T-E | Human | Esophagus | ESCC | 4.11e-02 | 1.09e-01 | 0.1067 |
| 1062 | CENPE | P52T-E | Human | Esophagus | ESCC | 1.39e-09 | 3.80e-01 | 0.1555 |
| 1062 | CENPE | P62T-E | Human | Esophagus | ESCC | 3.69e-02 | 2.31e-01 | 0.1302 |
| 1062 | CENPE | P74T-E | Human | Esophagus | ESCC | 9.63e-10 | 6.89e-01 | 0.1479 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:014001414 | Esophagus | ESCC | mitotic nuclear division | 218/8552 | 287/18723 | 6.17e-26 | 1.78e-23 | 218 |
| GO:005165617 | Esophagus | ESCC | establishment of organelle localization | 273/8552 | 390/18723 | 9.13e-23 | 1.81e-20 | 273 |
| GO:000007011 | Esophagus | ESCC | mitotic sister chromatid segregation | 138/8552 | 168/18723 | 1.37e-22 | 2.63e-20 | 138 |
| GO:00008194 | Esophagus | ESCC | sister chromatid segregation | 157/8552 | 202/18723 | 8.41e-21 | 1.33e-18 | 157 |
| GO:003304416 | Esophagus | ESCC | regulation of chromosome organization | 145/8552 | 187/18723 | 3.80e-19 | 4.31e-17 | 145 |
| GO:000705911 | Esophagus | ESCC | chromosome segregation | 238/8552 | 346/18723 | 1.72e-18 | 1.82e-16 | 238 |
| GO:004477216 | Esophagus | ESCC | mitotic cell cycle phase transition | 281/8552 | 424/18723 | 4.63e-18 | 4.45e-16 | 281 |
| GO:190285015 | Esophagus | ESCC | microtubule cytoskeleton organization involved in mitosis | 116/8552 | 147/18723 | 1.25e-16 | 9.91e-15 | 116 |
| GO:000734615 | Esophagus | ESCC | regulation of mitotic cell cycle | 293/8552 | 457/18723 | 8.00e-16 | 5.64e-14 | 293 |
| GO:000705214 | Esophagus | ESCC | mitotic spindle organization | 97/8552 | 120/18723 | 2.17e-15 | 1.33e-13 | 97 |
| GO:000705114 | Esophagus | ESCC | spindle organization | 134/8552 | 184/18723 | 5.70e-14 | 2.87e-12 | 134 |
| GO:005131011 | Esophagus | ESCC | metaphase plate congression | 58/8552 | 65/18723 | 1.81e-13 | 8.63e-12 | 58 |
| GO:000708011 | Esophagus | ESCC | mitotic metaphase plate congression | 47/8552 | 50/18723 | 3.15e-13 | 1.47e-11 | 47 |
| GO:00482853 | Esophagus | ESCC | organelle fission | 301/8552 | 488/18723 | 4.64e-13 | 2.12e-11 | 301 |
| GO:00988133 | Esophagus | ESCC | nuclear chromosome segregation | 187/8552 | 281/18723 | 1.00e-12 | 4.36e-11 | 187 |
| GO:005130311 | Esophagus | ESCC | establishment of chromosome localization | 67/8552 | 80/18723 | 1.92e-12 | 8.09e-11 | 67 |
| GO:005000011 | Esophagus | ESCC | chromosome localization | 68/8552 | 82/18723 | 3.37e-12 | 1.32e-10 | 68 |
| GO:00002802 | Esophagus | ESCC | nuclear division | 270/8552 | 439/18723 | 1.17e-11 | 4.24e-10 | 270 |
| GO:190198713 | Esophagus | ESCC | regulation of cell cycle phase transition | 242/8552 | 390/18723 | 3.86e-11 | 1.26e-09 | 242 |
| GO:190199013 | Esophagus | ESCC | regulation of mitotic cell cycle phase transition | 191/8552 | 299/18723 | 1.35e-10 | 3.94e-09 | 191 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CENPE | SNV | Missense_Mutation | novel | c.1588N>C | p.Glu530Gln | p.E530Q | Q02224 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| CENPE | SNV | Missense_Mutation | novel | c.4882N>C | p.Tyr1628His | p.Y1628H | Q02224 | protein_coding | tolerated(1) | benign(0) | TCGA-A2-A3XZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| CENPE | SNV | Missense_Mutation | rs200997499 | c.6408N>C | p.Met2136Ile | p.M2136I | Q02224 | protein_coding | tolerated(0.78) | benign(0) | TCGA-A2-A4RW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| CENPE | SNV | Missense_Mutation | c.5684N>T | p.Arg1895Ile | p.R1895I | Q02224 | protein_coding | deleterious(0) | benign(0.265) | TCGA-A8-A083-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CENPE | SNV | Missense_Mutation | rs779464384 | c.2429N>T | p.Ser810Leu | p.S810L | Q02224 | protein_coding | tolerated(1) | benign(0) | TCGA-A8-A09N-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| CENPE | SNV | Missense_Mutation | c.4947N>C | p.Leu1649Phe | p.L1649F | Q02224 | protein_coding | tolerated(0.08) | possibly_damaging(0.473) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CENPE | SNV | Missense_Mutation | c.3721N>T | p.His1241Tyr | p.H1241Y | Q02224 | protein_coding | tolerated(0.07) | possibly_damaging(0.696) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CENPE | SNV | Missense_Mutation | c.3140C>A | p.Ser1047Tyr | p.S1047Y | Q02224 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CENPE | SNV | Missense_Mutation | novel | c.1527T>G | p.Asn509Lys | p.N509K | Q02224 | protein_coding | deleterious(0.02) | benign(0.025) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CENPE | SNV | Missense_Mutation | c.1334N>C | p.Asn445Thr | p.N445T | Q02224 | protein_coding | tolerated(0.35) | benign(0.001) | TCGA-AR-A0TS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1062 | CENPE | KINASE | inhibitor | GSK-923295 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |